Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22376 | 0.88 | MGAM (0.57) | MGAMEGLN1SRD5A2PIM1PIM2 | |
| SCHEMBL18372036 | 0.88 | SMN1; SMN2 (0.49) | MGAMEGLN1SRD5A2PTPN1MAP4K4 | |
| SCHEMBL7449066 | 0.86 | KMT2A (0.47) | MGAMMGLLMAOBKDM4EBACE1 | |
| SCHEMBL28072259 | 0.85 | MGAM (0.48) | MGAMSRD5A2 | |
| SCHEMBL1644022 | 0.84 | MGAM (0.57) | MGAMSRD5A2RXRARXRBRXRG | |
| SCHEMBL10465639 | 0.81 | MGAM (0.70) | MGAMSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL845818 | 0.79 | MGAM (0.62) | MGAMEGLN1MAP4K4KDM4EALDH1A1 | |
| SCHEMBL29365612 | 0.78 | MGAM (0.53) | MGAMEGLN1PIM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28708729 | 0.78 | MGAM (0.53) | MGAMEGLN1PIM1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6085748 | 0.78 | MGAM (0.60) | MGAMEGLN1MAP4K4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-4910327-A | Reacting a corresponding aromatic primary amine with a ketoester | AMERICAN CYANAMID COMPANY (US) | 1990-03-20 | — | — | US | disclosed |
| US-4843162-A | INTERMEDIATES FOR HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1989-06-27 | — | — | US | disclosed |
| US-4656283-A | HERBICIDAL INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1987-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | MGAM 2439/4885MGLL 10/4885EGLN1 2399/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | MGAM 2439/4885MGLL 10/4885EGLN1 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.